ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1882

Characterizing The C-Type Lectin Domain Family 4, Member C Gene (CLEC4C) Expression In Peripheral Blood From Rheumatoid Arthritis Patients

Annie Yarwood1, Joanna Cobb2, Kate McAllister1, Joanne Barnes1, Ernst R. Dow3, Michelle A. Penny3, Robert W. Hoffman3 and Anne Barton4,5, 1Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Central Manchester Foundation Trust, Manchester, United Kingdom, 3Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 4Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 5NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Gene Expression and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

A previous hypothesis-seeking study examining baseline phenotypic expression of mRNA in a Phase 2 clinical trial of tabalumab (also known as LA294 or LY2127399) suggested that expression of the gene CLEC4C might serve to help stratify patients for their clinical response to tabalumab. CLEC4C-expressing cells appear to mediate their immunoregulatory effects through direct cell-cell contact or indirectly through the production of cytokines including TGF-beta and IL-10 and appear to influence T regulatory cells via these mechanisms. We hypothesize that this immunoregulatory cell may have a role in pathogenesis of RA and may influence drug treatment response. The primary aim of our study was to characterise the phenotypic expression of the gene CLEC4C, as measured in peripheral blood among a well characterised cohort of rheumatoid arthritis patients receiving different therapies.

Methods:

Total RNA was extracted from whole blood and converted to cDNA. A total of 322 samples were available for analysis, consisting of four groups: 1) 93 healthy controls 2) 72 RA patients with recent onset disease receiving methotrexate 3) 85 RA patients who have failed methotrexate and are receiving a TNFi 4) 72 RA patients who had failed at least one TNFi due to lack of efficacy and were receiving another biologic.  Quantitative real time PCR was carried out to measure the expression of CLEC4C and three reference genes.  CLEC4C expression was normalised and quantified using the delta CT method.  Linear regression was used to correlate expression with treatment group.

Results:

A significant difference in CLEC4C expression was observed between sample groups (p=2.5×10-5).  CLEC4C expression was significantly higher in healthy individuals compared to all RA patients (p=8.9×10-6). All patient groups showed lower expression when compared to healthy controls and this difference is greatest in patients treated with biologic therapies including TNFi (Table 1). 

Table 1: Linear regression results comparing CLEC4C expression in patients and healthy controls

Group

Coefficient

Standard error

P value

95% confidence interval

Controls

Reference

–

–

–

–

MTX

-0.0018

0.0006

0.007

-0.0032

-0.0005

TNFi

-0.0027

0.0007

9.89×10-5

-0.0040

-0.0013

Other Biologic

-0.0027

0.0007

0.00036

-0.0042

-0.0012

Conclusion:

Differences in expression of CLEC4C were found between RA patients and age- and sex-matched healthy controls with statistically significant higher levels of expression of CLEC4C seen in healthy controls. Among RA patients the highest levels of CLEC4C were seen in the RA patients who had been treated only with methotrexate and were biological naive; lowest levels of CLEC4C in those treated with one or more biologic agent including TNFi. These results suggest that stratification for CLEC4C expression may be valuable to assure balance between patient subgroups in clinical trials in that difference in baseline CLEC4C expression could be a source of unanticipated bias influencing trial outcome. Finally, determining the biologic basis for these observed differences in CLEC4C gene expression among different subgroups of patients, based upon prior treatment, may help advance our understanding of disease pathogenesis in RA.


Disclosure:

A. Yarwood,

Eli Lilly and Company,

2;

J. Cobb,

Eli Lilly and Company,

2;

K. McAllister,

Eli Lilly and Company,

2;

J. Barnes,

Eli Lilly and Company,

2;

E. R. Dow,

Eli Lilly and Company,

9;

M. A. Penny,

Eli Lilly and Company,

9;

R. W. Hoffman,

Eli Lilly and Company,

9;

A. Barton,

Eli Lilly and Company,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterizing-the-c-type-lectin-domain-family-4-member-c-gene-clec4c-expression-in-peripheral-blood-from-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology